Phase 3 EMERALD Trial: Recent Post Hoc Exploratory Analysis of Progression-Free Survival (PFS) Across Subgroups
Along with the Oncology Brothers, Paolo Tarantino, MD, discuss the phase 3 EMERALD study of elacestrant versus standard-of-care endocrine therapy for estrogen receptor-positive (ER+), HER2-negative (HER2-) metastatic breast cancer (MBC). Their conversation focuses on the implications of recently published data demonstrating that elacestrant provides a PFS benefit across clinically meaningful subgroups of patients with ESR1-mutated (ESR1m), ER+, HER2- MBC, including those with endocrine-sensitive disease.
Bardia A, Cortés J, Bidard FC, et al. Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Clin Cancer Res. 2024;30:4299-4309. https://doi.org/10.1158/1078-0432.CCR-24-1073.
EP. 1: Overview of phase 3 EMERALD study of elacestrant for ER+, HER2- MBC
November 22nd 2024Along with the Oncology Brothers, Paolo Tarantino, MD, provides an overview of the phase 3 EMERALD study that evaluated the efficacy of elacestrant as a second-line treatment for ER+, HER2- MBC, particularly in patients with tumors harboring an ESR1 mutation.
Watch
EP. 2: Episode 2: Incidence of ESR1 mutations and best practices for testing
November 25th 2024Along with the Oncology Brothers, Paolo Tarantino, MD, discusses how ESR1 mutations are commonly observed in hormone receptor-positive breast cancer after prolonged endocrine therapy, and emphasizes the importance of molecular testing for ESR1 mutations at both the initial diagnosis of MBC and at each subsequent progression using liquid biopsy assays.
Watch
EP. 3: Co-occurrence of ESR1 mutations with other alterations
November 25th 2024Along with the Oncology Brothers, Paolo Tarantino, MD, explores how ESR1 mutations frequently co-occur with other molecular alterations and the importance of maximizing endocrine-based therapy before moving on to antibody-drug conjugates or chemotherapy.
Watch
EP. 4: Elacestrant as second-line therapy for ESR1-mutated, endocrine-sensitive disease
November 25th 2024Along with the Oncology Brothers, Paolo Tarantino, MD, elaborates on results from an analysis of data from the EMERALD study that were reported at the San Antonio Breast Cancer Symposium (SABCS) 2022. This analysis identified duration of prior CDK4/6 inhibitor therapy as a potential surrogate marker for endocrine sensitivity, and discusses how these findings could help guide patient selection for elacestrant.
Watch
EP. 5: EMERALD subgroup analysis: Elacestrant in endocrine-sensitive disease
November 25th 2024Along with the Oncology Brothers, Paolo Tarantino, MD, discusses the post -hoc subgroup analysis from the EMERALD study (SABCS 2023), which examined outcomes in patients with ESR1 mutations (ESR1m) who had been on CDK4/6 inhibitors (CDK4/6i) plus endocrine therapy for 12 months or longer, and shares her his perspectives on how these findings may influence the use of elacestrant in ER+/HER2–- metastatic breast cancer (MBC) and impact clinical practice for community oncologists.
Watch
EP. 6: Elacestrant: Clinical Pearls for Adverse Effect Management
November 25th 2024Along with the Oncology Brothers, Paolo Tarantino, MD, discusses what has been learned about the safety profile of elacestrant and shares clinical pearls for adverse event management, aimed at helping patients remain on therapy while maximizing their quality of life.
Watch
EP. 7: Emerging data on oral selective estrogen receptor degraders
November 25th 2024Along with the Oncology Brothers, Paolo Tarantino, MD, discusses ongoing studies investigating oral selective estrogen receptor degraders, including trials exploring use of elacestrant in combination with other therapies.
Watch
